114 results on '"Kang, Yu Mi"'
Search Results
2. The Impact of Fasciation on Maize Inflorescence Architecture
- Author
-
Kim, Da Eun, Jeong, Jin-hee, Kang, Yu Mi, Park, Young-Hoon, Lee, Yong-Jae, Kang, Jum-soon, Choi, Young-Whan, Son, Beung-Gu, Kim, Sun Tae, Jackson, Dave, and Je, Byoung Il
- Published
- 2022
- Full Text
- View/download PDF
3. Exploring the impact of number and type of comorbidities on the risk of severe COPD exacerbations in Korean Population: a Nationwide Cohort Study
- Author
-
Kim, Youngmee, Kim, Ye-Jee, Kang, Yu Mi, and Cho, Won-Kyung
- Published
- 2021
- Full Text
- View/download PDF
4. Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study
- Author
-
Cho, Yun Kyung, Kang, Yu Mi, Yoo, Jee Hee, Lee, Jiwoo, Park, Joong-Yeol, Lee, Woo Je, Kim, Ye-Jee, and Jung, Chang Hee
- Published
- 2019
- Full Text
- View/download PDF
5. Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study
- Author
-
Yoo, Jee Hee, Cho, Yun Kyung, Lee, Jiwoo, Kim, Hwi Seung, Kang, Yu Mi, Jung, Chang Hee, Park, Joong-Yeol, and Lee, Woo Je
- Published
- 2019
- Full Text
- View/download PDF
6. The Impact of NAFLD and Waist Circumference Changes on Diabetes Development in Prediabetes Subjects
- Author
-
Lee, Jiwoo, Cho, Yun Kyung, Kang, Yu Mi, Kim, Hwi Seung, Jung, Chang Hee, Kim, Hong-Kyu, Park, Joong-Yeol, and Lee, Woo Je
- Published
- 2019
- Full Text
- View/download PDF
7. Association between serum gamma-glutamyltransferase and the progression of coronary artery calcification
- Author
-
Cho, Yun Kyung, Kang, Yu Mi, Hwang, Jenie Yoonoo, Kim, Eun Hee, Yang, Dong Hyun, Kang, Joon-Won, Park, Joong-Yeol, Lee, Woo Je, Kim, Hong-Kyu, and Jung, Chang Hee
- Published
- 2015
- Full Text
- View/download PDF
8. Dehydroepiandrosterone prevents linoleic acid-induced endothelial cell senescence by increasing autophagy
- Author
-
Lee, Min Jung, Kim, Eun Hee, Lee, Sang Ah., Kang, Yu Mi, Jung, Chang Hee, Yoon, Hae Kyeong, Seol, So Mi, La Lee, Yoo, Lee, Woo Je, and Park, Joong-Yeol
- Published
- 2015
- Full Text
- View/download PDF
9. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification
- Author
-
Cho, Yun Kyung, Kang, Yu Mi, Yoo, Jee Hee, Lee, Jiwoo, Lee, Seung Eun, Yang, Dong Hyun, Kang, Joon-Won, Park, Joong-Yeol, Jung, Chang Hee, Kim, Hong-Kyu, and Lee, Woo Je
- Published
- 2018
- Full Text
- View/download PDF
10. The Survival Role of Peroxisome Proliferator-activated Receptor Gamma Induces Odontoblast Differentiation against Oxidative Stress in Human Dental Pulp Cells
- Author
-
Lee, Young-Hee, Kang, Yu-Mi, Heo, Mi-Ja, Kim, Go-Eun, Bhattarai, Govinda, Lee, Nan-Hee, Yu, Mi-Kyung, and Yi, Ho-Keun
- Published
- 2013
- Full Text
- View/download PDF
11. Cardiovascular Diseases and Life Expectancy in Adults With Type 2 Diabetes: A Korean National Sample Cohort Study
- Author
-
Kang, Yu Mi, Cho, Yun Kyung, Lee, Seung Eun, Park, Joong-Yeol, Lee, Woo Je, Kim, Ye-Jee, and Jung, Chang Hee
- Published
- 2017
12. Life Span and Thymic Lymphoma Incidence in High- and Low-Dose-Rate Irradiated AKR/J Mice and Commonly Expressed Genes
- Author
-
Shin, Suk Chul, Kang, Yu Mi, and Kim, Hee Sun
- Published
- 2010
13. The Risk of Incident Type 2 Diabetes in a Korean Metabolically Healthy Obese Population: The Role of Systemic Inflammation
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Jang, Jung Eun, Leem, Jaechan, Hwang, Jenie Yoonoo, Kim, Eun Hee, Park, Joong-Yeol, Kim, Hong-Kyu, and Lee, Woo Je
- Published
- 2015
14. Association of Serum C1q/TNF-Related Protein-9 Concentration With Arterial Stiffness in Subjects With Type 2 Diabetes
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Jang, Jung Eun, Leem, Jaechan, Lee, Yoo La, Seol, So Mi, Yoon, Hae Kyeong, Lee, Woo Je, and Park, Joong-Yeol
- Published
- 2014
15. SGLT2 INHIBITORS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES AT HIGH RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HEART FAILURE OR CHRONIC KIDNEY DISEASE: A SMART-C COLLABORATIVE META-ANALYSIS.
- Author
-
Patel, Siddharth M., Kang, Yu Mi, Im, KyungAh, Neuen, Brendon, Heerspink, Hiddo Lambers, Sabatine, Marc Steven, and Wiviott, Stephen
- Subjects
- *
CHRONIC kidney failure , *CARDIOVASCULAR diseases , *SODIUM-glucose cotransporter 2 inhibitors , *HEART failure , *PEOPLE with diabetes , *IVABRADINE - Published
- 2024
- Full Text
- View/download PDF
16. The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects.
- Author
-
Yoo, Jee Hee, Kang, Yu Mi, Cho, Yun Kyung, Lee, Jiwoo, Jung, Chang Hee, Park, Joong‐Yeol, Ryu, Ohk‐Hyun, Kim, Hong‐Kyu, and Lee, Woo Je
- Subjects
- *
FATTY liver , *MULTIPLE regression analysis , *LOGISTIC regression analysis , *HEMOGLOBINS , *GLYCOSYLATED hemoglobin - Abstract
Objectives: The hemoglobin glycation index (HGI) quantifies interindividual variations in glycated hemoglobin (HbA1c) and is associated with diabetic complications and metabolic diseases. However, information on the association between HGI and non‐alcoholic fatty liver disease (NAFLD) in healthy subjects is limited, particularly in Asian populations. This study aimed to investigate the association between HGI and NAFLD in a healthy Korean cohort. Design: Subjects were stratified in quartiles according to their HGI level. NAFLD was diagnosed by hepatic ultrasonography, hepatic steatosis index and fatty liver index. Multiple logistic regression analysis was performed to evaluate the association between HGI quartiles and the risk of NAFLD. Patients: Data from subjects without diabetes who underwent liver ultrasonography during routine health examinations were retrospectively reviewed. Results: Data from 14 465 subjects were included in the analysis. The prevalence of NAFLD increased significantly with each HGI quartile (24.8%, 29.7%, 32.6% and 40.6% in quartiles 1‐4, respectively; P < 0.001). In comparison with the lowest HGI quartile group, the highest quartile exhibited worse metabolic parameters, including body weight, waist circumference, body mass index and lipid profiles. Multiple logistic regression analysis adjusted for multiple factors showed that the odds ratio of having NAFLD was 1.564 (95% CI: 1.350‐1.813, P < 0.001) in the highest HGI quartile. Conclusions: Elevated HGI levels are independently associated with NAFLD in a healthy Asian population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
- Author
-
Cho, Yun Kyung, Lee, Jiwoo, Kang, Yu Mi, Yoo, Jee Hee, Park, Joong-Yeol, Jung, Chang Hee, and Lee, Woo Je
- Subjects
TYPE 2 diabetes ,GLYCEMIC index ,WEIGHT loss ,GLOMERULAR filtration rate ,BODY weight - Abstract
We aimed to investigate the clinical factors affecting the therapeutic effectiveness of the sodium–glucose cotransporter-2 inhibitor empagliflozin in patients with type 2 diabetes mellitus (T2DM). We reviewed the medical records of 374 T2DM patients aged between 20 and 75 years who were prescribed empagliflozin 10 mg or 25 mg as add-on therapy for more than 90 consecutive days. Changes in hemoglobin A1c (HbA1c) from baseline levels and the reduction in body weights of the study participants were assessed. We found that younger patients (≤ 50 years), patients with the highest levels of HbA1c (>9%) at baseline, patients with an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m
2 , and patients with a shorter duration of T2DM (< 10 years) were more likely to exhibit a better glycemic response. Multivariate linear regression analysis revealed that a shorter duration of T2DM, higher baseline levels of HbA1c, and higher eGFR were positively associated with HbA1c reduction. Higher BMI and lower HbA1c levels were predictors of a more significant reduction in body weight among patients taking empagliflozin. The glucose-lowering effect of empagliflozin was more evident in T2DM patients with higher baseline HbA1c levels, better renal function, and shorter duration of T2DM. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
18. Comparison between sodium–glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta‐analysis.
- Author
-
Cho, Yun Kyung, Kim, Ye‐Jee, Kang, Yu Mi, Lee, Seung Eun, Park, Joong‐Yeol, Lee, Woo Je, and Jung, Chang Hee
- Subjects
SODIUM-glucose cotransporters ,PIOGLITAZONE ,INSULIN therapy ,TYPE 2 diabetes treatment ,DRUG efficacy ,MEDICATION safety ,THERAPEUTICS - Abstract
Abstract: Aims/Introduction: We aimed to evaluate the efficacy and safety of pioglitazone (PIO) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) as additions to insulin therapy for the management of type 2 diabetes mellitus. Materials and Methods: We searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov through December 2016. Randomized controlled trials published in English that compared SGLT2i plus insulin (SGLT2i/INS) or PIO plus insulin (PIO/INS) with placebo plus insulin (PCB/INS) in type 2 diabetes mellitus patients were included. We compared the efficacy and safety between SGLT2i/INS and PIO/INS indirectly. Results: A total of 14 randomized controlled trials comparing 7,226 participants were included (8 SGLT2i and 6 PIO studies). SGLT2i/INS achieved similar reductions in hemoglobin A1c (weighted mean difference [WMD] −0.01% [−0.1 mmol/mol], 95% confidence interval [CI] −0.25 to 0.22% [−2.7 to −2.4 mmol/mol]; P = 0.896) and fasting plasma glucose (WMD −0.90 mg/dL, 95% CI: −15.50 to 13.71 mg/dL; P = 0.904), and a similar proportion of participants achieved hemoglobin A1c <7.0% (<53.0 mmol/mol; relative risk 0.98, 95% CI: 0.73 to 1.33; P = 0.917) as compared with the PIO/INS group, with greater weight reduction (WMD −4.54 kg, 95% CI: −5.67 to −3.41 kg; P < 0.001). PIO/INS showed non‐significant trends toward a higher risk of hypoglycemia (relative risk 1.15, 95% CI: 0.97 to 1.35; P = 0.102) and higher reduction of total daily insulin doses (WMD −2.45 IU/day, 95% CI: −7.30 to 2.40 IU/day; P = 0.438). Conclusions: Both PIO and SGLT2i are feasible adjunctive oral agents to pre‐existing insulin therapy in individuals with inadequately controlled type 2 diabetes mellitus. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Effect of SFRP5 (Secreted Frizzled–Related Protein 5) on the WNT5A (Wingless-Type Family Member 5A)-Induced Endothelial Dysfunction and Its Relevance With Arterial Stiffness in Human Subjects.
- Author
-
Cho, Yun Kyung, Kang, Yu Mi, Lee, Seung Eun, Lee, Yoo La, Seol, So Mi, Lee, Woo Je, Park, Joong-Yeol, and Jung, Chang Hee
- Published
- 2018
- Full Text
- View/download PDF
20. Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009–2013).
- Author
-
Lee, Seung Eun, Han, Kyungdo, Kang, Yu Mi, Kim, Seon-Ok, Cho, Yun Kyung, Ko, Kyung Soo, Park, Joong-Yeol, Lee, Ki-Up, Koh, Eun Hee, and null, null
- Subjects
DISEASE prevalence ,METABOLIC syndrome treatment ,HEALTH insurance ,MEDICAL education ,PUBLIC health - Abstract
Background: The prevalence of metabolic syndrome has markedly increased worldwide. However, studies in the United States show that it has remained stable or slightly declined in recent years. Whether this applies to other countries is presently unclear. Objectives: We examined the trends in the prevalence of metabolic syndrome and its components in Korea. Methods: The prevalence of metabolic syndrome and its components was estimated in adults aged >30 years from the Korean National Health Insurance Service data from 2009 to 2013. The revised National Cholesterol Education Program criteria were used to define metabolic syndrome. Results: Approximately 10 million individuals were analyzed annually. The age-adjusted prevalence of metabolic syndrome increased from 28.84% to 30.52%, and the increasing trend was more prominent in men. Prevalence of hypertriglyceridemia, low HDL-cholesterol, and impaired fasting plasma glucose significantly increased. However, the prevalence of hypertension decreased in both genders. The prevalence of abdominal obesity decreased in women over 50 years-of-age but significantly increased in young women and men (<50 years). Conclusions: The prevalence of metabolic syndrome is still increasing in Korea. Trends in each component of metabolic syndrome are disparate according to the gender, or age groups. Notably, abdominal obesity among young adults increased significantly; thus, interventional strategies should be implemented particularly for this age group. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice.
- Author
-
Jang, Jung Eun, Park, Han‐Sol, Yoo, Hyun Ju, Baek, In‐Jeoung, Yoon, Ji Eun, Ko, Myoung Seok, Kim, Ah‐Ram, Kim, Hyoun Sik, Park, Hye‐Sun, Lee, Seung Eun, Kim, Seung‐Whan, Kim, Su Jung, Leem, Jaechan, Kang, Yu Mi, Jung, Min Kyo, Pack, Chan‐Gi, Kim, Chong Jai, Sung, Chang Ohk, Lee, In‐Kyu, and Park, Joong‐Yeol
- Published
- 2017
- Full Text
- View/download PDF
22. Visceral adiposity index predicts the conversion of metabolically healthy obesity to an unhealthy phenotype.
- Author
-
Kang, Yu Mi, Jung, Chang Hee, Cho, Yun Kyung, Jang, Jung Eun, Hwang, Jenie Yoonoo, Kim, Eun Hee, Lee, Woo Je, Park, Joong-Yeol, and Kim, Hong-Kyu
- Subjects
- *
OBESITY , *PHENOTYPES , *ANTHROPOMETRY , *FOLLOW-up studies (Medicine) , *MATHEMATICAL models - Abstract
Objective: Some individuals with metabolically healthy obesity (MHO) convert to metabolically unhealthy obesity (MUO) phenotype, and visceral adiposity is one of proposed mechanisms underlying such conversion. Visceral adipose index (VAI) is a novel mathematical model which estimates visceral adiposity based on anthropometric and lipid profiles. We aimed to determine the association of VAI-estimated visceral adiposity with the MHO-to-MUO conversion and the predictive value of VAI in estimating such unfavorable outcomes. Methods: A total of 2,204 Korean subjects with the MHO phenotype were enrolled and stratified by body mass index and metabolic health state according to Wildman criteria at baseline and last follow-up examinations. VAI was calculated at baseline. Results: Over a median follow-up period of 41.1 months, 46.0% of subjects converted to MUO phenotype. Higher VAI quartiles were associated with a greater proportion of subjects who underwent MHO-to-MUO conversion, and also with increased odds ratios for such conversion even after multivariate analyses. The optimal VAI cut off value was around 1.00, and VAI had a greater power in the prediction of MHO-to MUO conversion than waist circumference in both genders. Conclusion: MHO phenotypes with high VAI values are associated with poor future metabolic outcomes. VAI-estimated visceral adiposity is well correlated with the prognosis of MHO subjects, and VAI has a good predictive value in determining the MHO-to-MUO conversion. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population.
- Author
-
Kang, Yu Mi, Jung, Chang Hee, Cho, Yun Kyung, Lee, Seung Eun, Lee, Min Jung, Hwang, Jenie Yoonoo, Kim, Eun Hee, Park, Joong-Yeol, Lee, Woo Je, and Kim, Hong-Kyu
- Subjects
- *
CORONARY artery bypass , *CALCIFICATION , *LIVER diseases , *FATTY degeneration , *DISEASE progression - Abstract
Objectives: Metabolically healthy obese (MHO) phenotype describes an obese state with a favorable metabolic profile. However, the prognosis of this subpopulation remains controversial. We aimed to examine whether MHO phenotype is associated with progression of atherosclerotic activity, reflected as the changes in coronary artery calcification (CAC) over time. If so, we sought to determine the role of fatty liver disease (FLD), the hallmark of hepatic steatosis, in this progression. Methods: We enrolled 1,240 asymptomatic subjects who underwent repeated CAC score measurement during routine health examinations. CAC score progression was defined as either incident CAC in a population free of CAC at baseline, or an increase by ≥2.5 units between the baseline and final square root of CAC scores in participants with detectable CAC at baseline. Subjects were stratified by body mass index (cut-off, 25.0 kg/m2) and metabolic health state using Adult Treatment Panel-III criteria. FLD was assessed via ultrasonography. Results: Over 2.9 years of follow-up, 25.2% of total subjects exhibited CAC score progression. The MHO phenotype was not significantly associated with CAC score progression (multivariate adjusted-odds ratio [OR], 1.45; 95% confidence interval [CI], 0.93–2.25), as compared to the metabolically healthy non-obese (MHNO) phenotype. However, subgroup analysis indicated that the MHO/FLD phenotype was significantly associated with CAC score progression (multivariate adjusted-OR, 2.37; 95% CI, 1.34–4.16), as compared to the MHNO/no FLD phenotype, whereas the MHO/no FLD phenotype was not (multivariate adjusted OR, 1.25; 95% CI, 0.71–2.24). Conclusions: Obese individuals with FLD have an increased risk of atherosclerosis progression, despite their healthy metabolic profile. Preventive interventions targeting cardiometabolic risk factors should be considered in such individuals, regardless of the weight status. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. The association of incident hypertension with metabolic health and obesity status: definition of metabolic health does not matter.
- Author
-
Kang, Yu Mi, Jung, Chang Hee, Jang, Jung Eun, Hwang, Jenie Yoonoo, Kim, Eun Hee, Park, Joong‐Yeol, Kim, Hong‐Kyu, and Lee, Woo Je
- Subjects
- *
HYPERTENSION , *OVERWEIGHT persons , *METABOLIC profile tests , *PHENOTYPES , *OBESITY - Abstract
Objective Metabolically healthy obese (MHO) phenotype refers to obese individuals with a favourable metabolic profile. Its prognostic value remains controversial and may partly depend on differences in how the phenotype is defined. We aimed to investigate whether the MHO phenotype is associated with future development of incident hypertension in a Korean population according to various definitions of metabolic health. Subjects and Methods The study population comprised 31 033 Koreans without hypertension. Participants were stratified into metabolically healthy nonobese (MHNO), metabolically unhealthy nonobese (MUNO), metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) by body mass index (cut-off value, 25·0 kg/m2) and metabolic health state, using four different definitions: Adult Treatment Panel (ATP)-III, Wildman, Karelis and the homoeostasis model assessment (HOMA) criteria. Results Over the median follow-up period of 35·0 months (range, 4·5-81·4 months), 4589 of the 31 033 individuals (14·8%) developed incident hypertension. Compared with the MHNO group, the MHO group showed increased association with incident hypertension with multivariate-adjusted odds ratios of 1·56 (95% confidence interval [CI], 1·41-1·72), 1·58 (95% CI 1·42-1·75), 1·52 (95% CI 1·35-1·71) and 1·46 (95% CI 1·33-1·61), when defined by ATP-III, Wildman, Karelis and HOMA criteria, respectively. Conclusion MUO individuals showed the highest association with the incident hypertension (adjusted odds ratios up to 2·00). MHO subjects showed an approximately 1·5-fold higher association with incident hypertension than their nonobese counterpart regardless of the definition of metabolic health used. Thus, considering both metabolic health and obesity is important for the assessment of potential cardiovascular outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. 2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population.
- Author
-
Cho, Yun Kyung, Jung, Chang Hee, Kang, Yu Mi, Hwang, Jenie Yoonoo, Kim, Eun Hee, Yang, Dong Hyun, Kang, Joon ‐ Won, Park, Joong ‐ Yeol, Kim, Hong ‐ Kyu, Lee, Woo Je, Kang, Joon-Won, Park, Joong-Yeol, and Kim, Hong-Kyu
- Published
- 2016
- Full Text
- View/download PDF
26. Fatty liver index is a risk determinant of incident type 2 diabetes in a metabolically healthy population with obesity.
- Author
-
Jung, Chang Hee, Kang, Yu Mi, Jang, Jung Eun, Hwang, Jenie Yoonoo, Kim, Eun Hee, Park, Joong ‐ Yeol, Kim, Hong ‐ Kyu, and Lee, Woo Je
- Subjects
FATTY liver ,TYPE 2 diabetes ,OBESITY ,TRIGLYCERIDES ,BODY mass index ,DISEASE risk factors - Abstract
Objective: This study investigated the effect of fatty liver disease (FLD) on the risk of incident type 2 diabetes in a population with metabolically healthy obesity (MHO).Methods: The study population comprised 34,258 Koreans without type 2 diabetes. Participants were stratified by BMI (cutoff value, 25.0 kg/m(2) ) and metabolic health state (using Wildman criteria). FLD was defined by the fatty liver index (FLI), a predictive algorithm to detect FLD. Subjects were classified into low and high FLI groups based on tertile.Results: At baseline, there were significant differences in FLI between four study groups. During a median follow-up of 36.5 months, 1.7% individuals developed type 2 diabetes. The risk of incident type 2 diabetes varied for the MHO group according to the level of FLI. The risk of type 2 diabetes in the MHO with low FLI was not significantly elevated compared with the metabolically healthy individuals without obesity (MHNO) with low FLI (multivariate-adjusted HR, 1.19 [95% CI 0.66-2.14]). However, the MHO with high FLI had an elevated risk of incident type 2 diabetes (multivariate-adjusted HR, 1.99 [95% CI 1.36-2.92]).Conclusions: MHO subjects have a substantially higher risk of incident type 2 diabetes than MHNO subjects. The presence of FLD assessed by FLI partially explains this increased risk. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. 2013 ACC/AHA versus 2004 NECP ATP III Guidelines in the Assignment of Statin Treatment in a Korean Population with Subclinical Coronary Atherosclerosis.
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Yang, Dong Hyun, Kang, Joon-Won, Kim, Eun Hee, Park, Duk-Woo, Park, Joong-Yeol, Kim, Hong-Kyu, and Lee, Woo Je
- Subjects
ATHEROSCLEROSIS treatment ,STATINS (Cardiovascular agents) ,BLOOD cholesterol ,ANGIOGRAPHY ,CORONARY artery stenosis ,THERAPEUTICS - Abstract
Background: The usefulness of the 2013 ACC/AHA guidelines for the management of blood cholesterol in the Asian population remains controversial. In this study, we investigated whether eligibility for statin therapy determined by the 2013 ACC/AHA guidelines is better aligned with the presence of subclinical coronary atherosclerosis detected by CCTA (coronary computed tomography angiography) compared to the previously recommended 2004 NCEP ATP III guidelines. Methods: We collected the data from 5,837 asymptomatic subjects who underwent CCTA using MDCT during routine health examinations. Based on risk factor assessment and lipid data, we determined guideline-based eligibility for statin therapy according to the 2013 ACC/AHA and 2004 NCEP ATP III guidelines. We defined the presence and severity of subclinical coronary atherosclerosis detected in CCTA according to the presence of significant coronary artery stenosis (defined as >50% stenosis), plaques, and the degree of coronary calcification. Results: As compared to the 2004 ATP III guidelines, a significantly higher proportion of subjects with significant coronary stenosis (61.8% vs. 33.8%), plaques (52.3% vs. 24.7%), and higher CACS (CACS >100, 63.6% vs. 26.5%) was assigned to statin therapy using the 2013 ACC/AHA guidelines (P < .001 for all variables). The area under the curves of the pooled cohort equation of the new guidelines in detecting significant stenosis, plaques, and higher CACS were significantly higher than those of the Framingham risk calculator. Conclusions: Compared to the previous ATP III guidelines, the 2013 ACC/AHA guidelines were more sensitive in identifying subjects with subclinical coronary atherosclerosis detected by CCTA in an Asian population. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: A 4year retrospective longitudinal study.
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Hwang, Jenie Yoonoo, Jang, Jung Eun, Leem, Jaechan, Park, Joong-Yeol, Kim, Hong-Kyu, and Lee, Woo Je
- Subjects
BILIRUBIN ,DIABETES ,KOREANS ,HEME oxygenase ,DISEASES in men ,ANTIOXIDANTS ,METABOLIC disorders ,RETROSPECTIVE studies ,DISEASE risk factors ,DISEASES - Abstract
Abstract: Objective: Bilirubin, a natural product of heme catabolism by heme oxygenase, one of key antioxidant enzymes, has been recognized as a substance with potent antioxidant and cytoprotective properties. Several studies have shown a significant negative relationship between serum bilirubin levels and the risk of metabolic disorders, including type 2 diabetes. However, longitudinal studies investigating the association of elevated serum bilirubin levels and type 2 diabetes are lacking. In the present study, we aimed to investigate the longitudinal effects of baseline serum bilirubin concentrations on the development of type 2 diabetes in healthy Korean men. Materials and Methods: This 4year retrospective longitudinal observational study was conducted at the Asan Medical Center, Seoul, Republic of Korea. The study population consisted of 5960 men without type 2 diabetes who underwent routine health examinations in 2007 (baseline) and 2011 (follow-up). Baseline serum bilirubin concentrations were determined by the vanadate oxidation method. Results: During a 4year period, 409 incident cases of diabetes (6.9 %) were identified. Incident type 2 diabetes decreased across the baseline bilirubin quartile categories (P for trend <0.001). In multivariable-adjusted model, the relative risk (RR) for the development of type 2 diabetes was significantly lower in the highest (i.e., 1.30–2.00mg/dl) than in the lowest bilirubin quartile category (i.e., ≤0.90mg/dl), even after adjustment for confounding variables (RR=0.69, 95% confidence interval 0.48–0.99, P for trend=0.041). Conclusions: The results indicate that serum total bilirubin level may provide additional information for predicting future development of type 2 diabetes in healthy subjects. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
29. Identification of radiation-sensitive expressed genes in the ICR and AKR/J mouse thymus.
- Author
-
Bong, Jin Jong, Kang, Yu Mi, Shin, Suk Chul, Choi, Seung Jin, Lee, Kyung Mi, and Kim, Hee Sun
- Subjects
- *
RADIATION , *GENE expression , *LABORATORY mice , *THYMUS , *POLYMERASE chain reaction , *APOPTOSIS - Abstract
We have investigated radiation-sensitive expressed genes (EGs), their signal pathways, and the effects of ionizing radiation in the thymus of ICR and AKR/J mice. Whole-body and relative thymus weights were taken and microarray analyses were done on the thymuses of high-dose-rate (HDR, 137Cs, 0.8 Gy/min, a single dose of 4.5 Gy) and low-dose-rate (LDR, 137Cs, 0.7 mGy/h, a cumulative dose of 1.7 Gy) irradiated ICR and AKR/J mice. Gene expression patterns were validated by quantitative polymerase chain reaction (qPCR). The effect of ionizing radiation on thymus cell apoptosis was measured terminal deoxynucleotidyltransferase- mediated dUTP-end labeling (TUNEL). LDR-irradiation increased the mean whole-body weight, but decreased the relative thymus weight of AKR/J mice. Radiation-sensitive EGs were found by comparing HDR- and LDR-irradiated ICR and AKR/J mice. qPCR analysis showed that 12 EGs had dose and dose-rate dependent expression patterns. Gene-network analysis indicated that Ighg, Igh-VJ558, Defb6, Reg3g, and Saa2 may be involved in the immune response, leukocyte migration, and apoptosis. Our data suggest that expression of the HDR (Glut1, Glut4, and PKLR) and LDR radiation-response genes (Ighg and Igh-VJ558) can be dose or dose-rate dependent. There was an increased number of apoptotic cells in HDR-irradiated ICR mice and LDR-irradiated AKR/J mice. Thus, changes of the mean whole-body weight and relative thymus weight, EGs, signal pathways, and the effects of ionizing radiation on the thymus of ICR and AKR/J mice are described. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
30. 1014-P: The Impact of Baseline A1C and Admission Glucose on Mortality among Patients with Diabetes Hospitalized with COVID-19.
- Author
-
BRANCALE, JOSEPH, ATHONVARANGKUL, DIANA, SIMONOV, MICHAEL, ALAUSA, JAMEEL, SUBAIR, LABEEBAH K., HAJDUK, ALEXANDRA M., KANG, YU MI, ARORA, TANIMA, WILSON, FRANCIS P., JASTREBOFF, ANIA M., and LIPSKA, KASIA J.
- Abstract
We sought to determine the associations between hemoglobin A1c (A1c) and admission glucose with in-hospital mortality among patients with diabetes mellitus (DM) hospitalized with COVID-19. Adults hospitalized between 3/5/20 and 12/1/20 in a Connecticut health care system were included if they had prior DM diagnosis, an in-hospital A1c, and a positive RT-PCR nasopharyngeal swab for SARS-CoV-2. A1c was stratified into <7%, 7-<9%, and ≥9%. Both bivariate and multi-variable adjusted logistic regression analyses were performed to determine the association of A1c categories and admission glucose >200 mg/dL with mortality (in-hospital death or transition to hospice) and with intensive care unit (ICU) use. Models were adjusted for demographics and 8 relevant comorbidities. Among 733 patients (median age 67 years [interquartile range, 56-77], 48.3% female, 43.11% White, 35.47% Black, 24.97% Hispanic, 1.64% Asian), 31.7% had A1c <7%, 40.5% 7-<9%, 27.8% ≥9%, and 38.1% admission glucose >200 mg/dL. During hospitalization, 111 (15.1%) patients died or transitioned to hospice and 230 (31.4%) required ICU care. In 2 multi-variable adjusted analyses, neither A1c category nor high admission glucose were significantly associated with mortality (A1c 7-<9%: OR 0.89, 95% CI 0.53-1.49; A1c >9% OR 1.3, CI 0.72-2.35 compared with A1c <7%; glucose >200 OR 1.34, CI 0.72-2.35) or ICU care (A1c 7-<9% OR 1.30, 95% CI 0.88-1.93; A1c ≥9% OR 1.35, CI 0.86-2.1 compared with A1c <7%; glucose >200 OR 1.26, CI 0.9-1.78). Age (per year OR 1.06, CI 1.04-1.08), male sex (OR 1.78, CI 1.14-2.81), obesity (OR 1.85, CI 1.16-2.96) and CKD (OR 1.90, CI 1.19-3.03) were significantly associated with mortality. Only female sex (OR 0.67, CI 0.48-0.93) was significantly associated with ICU care. In our retrospective study of hospitalized patients with DM, neither A1c nor admission glucose were prognostic of COVID-19 mortality or ICU care. In those with DM, male sex, obesity and CKD predicted worse outcomes. Disclosure: J. Brancale: None. A. M. Jastreboff: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk, Other Relationship; Spouse/Partner; Elucidata. K. J. Lipska: None. D. Athonvarangkul: None. M. Simonov: None. J. Alausa: None. L. K. Subair: None. A. M. Hajduk: None. Y. Kang: None. T. Arora: None. F. P. Wilson: Other Relationship; Self; Efference LLC, Medscape. Funding: National Institutes of Health (1T32GM136651-01) [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Sperm abnormalities in high- and low-dose-rate Γ-irradiated Korean dark-striped field mice, Apodemus agrarius coreae.
- Author
-
Woon, Jae-Ho, Shin, Suk-Chul, Kang, Yu-Mi, and Kim, Hee-Sun
- Subjects
RADIATION measurements ,APODEMUS ,GAMMA ray sources ,ANIMAL germplasm ,IRRADIATION - Abstract
To evaluate the in vivo effects of low-dose-rate (0.7 mGy h–1) gamma radiation, abnormal shapes of sperm in the caudal epidydimus of Apodemus agrarius coreae (A. a. coreae) were used. The six categories of abnormal forms (amorphous heads, blunt hooks, excessive hooks, two heads and tails, folded tails and short tails) of sperm were observed eight days after gamma irradiation (0, 0.5, 1 and 2 Gy) with a high dose rate (0.8 Gy min–1) and a low dose rate. The frequency of total abnormal sperm gradually increased starting from 0.5 Gy after high-dose-rate radiation. Blunt hooks and short tails shaped sperm, in particular, were gradually increasing in the high-dose-rate irradiated mice. Dose rate reduction effects for the frequency of abnormal sperms in low-dose-rate irradiated mice to high-dose-rate irradiated mice were 1 at 0.5 Gy, 0.7 at 1 Gy and 0.5 at 2 Gy. Our results indicate that low-dose-rate radiation is not detrimental to spermatogenic cells. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
32. 1341-P: Association of NAFLD with Diabetes and the Impact of Waist Circumference and BMI Changes in Subjects with Prediabetes.
- Author
-
LEE, JIWOO, KANG, YU MI, PARK, JOONG-YEOL, and LEE, WOO JE
- Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) and prediabetes are well-known risk factors for diabetes. However, few studies have been performed about the risk of diabetes in subjects with prediabetes in the presence of NAFLD. In addition, little information was known about the impact of waist circumference (WC) and body mass index (BMI) changes on the development of diabetes. In this study, we examined the association of NAFLD with diabetes and the impact of WC and BMI changes in subjects with prediabetes. Methods: We enrolled 6,240 subjects with prediabetes who underwent general routine health evaluations in 2007 and returned for follow-up examinations in 2008 -2013 at least one time. Subjects were stratified by WC and BMI changes into three groups. The relative ratios (RRs) of NAFLD for diabetes was evaluated. Results: The prevalence of NAFLD in study participants was 45.4% (2,830/6,240). Subjects with NAFLD had higher BMI, WC, HbA1c levels, blood pressure levels, blood lipid levels, and also higher ALT levels (P < 0.001). During the follow-up, the total incidence of diabetes was 8.093%. Subjects with NAFLD at baseline had a higher incidence of diabetes and the adjusted RRs were 2.181 [95% confidence interval (CI), 1.778 to 2.674]. Furthermore, the RRs were closely related to WC changes. The adjusted RRs for diabetes according to WC change (≤ 0.0 cm, 0 cm to 3.0 cm, and > 3.0 cm) were 1.953 (95% CI, 1.365 to 2.794), 1.996 (95% CI, 1.407 to 2.833), and 2.302 (95% CI, 1.598 to 3.314), respectively. Furthermore, the RRs were also closely related to BMI changes and the adjusted RRs for diabetes according to BMI change (< -0.35 kg/m2, -0.35 kg/m2 to 0.35 kg/m2, and > 0.35 kg/m2) were 1.633 (95% CI, 1.121 to 2.380), 1.995 (95% CI, 1.415 to 2.811), and 2.924 (95% CI, 2.053 to 4.165), respectively. Conclusion: There was a strong and independent association between NAFLD and diabetes in Korean subjects with prediabetes, and this relationship was closely related to WC and BMI changes. Disclosure: J. Lee: None. Y. Kang: None. J. Park: None. W. Lee: None. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. 1667-P: Hemoglobin Glycation Index Is Associated with Nonalcoholic Fatty Liver Disease in Healthy Population.
- Author
-
YOO, JEE HEE, LEE, WOO JE, PARK, JOONG-YEOL, LEE, JIWOO, KANG, YU MI, JUNG, CHANG HEE, CHO, YUN KYUNG, and PARK, CHEOL-YOUNG
- Abstract
Aims: Hemoglobin glycation index (HGI), which quantifies interindividual variations in glycated hemoglobin (HbA1c), is known to be associated with diabetic complications and metabolic diseases. However, information on the association between HGI and nonalcoholic fatty liver disease (NAFLD) in healthy population, especially in Asian population is limited. Methods: A total of 14,465 subjects without diabetes who underwent liver ultrasonography during routine health examination were enrolled and stratified in quartiles according to HGI levels. Results: The prevalence of NAFLD significantly increased with HGI quartiles (24.8%, 29.7%, 32.6% and 40.6% in the 1
st , 2nd , 3rd , and 4th HGI quartiles, respectively; p-value<0.001). As compared with the lowest HGI quartile group, the highest HGI quartile group had worse metabolic parameters including body weight, waist circumference, body mass index and lipid profiles. In the multiple logistic regression analysis adjusted for multiple factors, the odds ratio of having NAFLD was 1.564 (95% CI: 1.350-1.813, p <0.001) in the highest HGI quartile group. Conclusions: Elevated HGI levels are independently associated with prevalence of NAFLD in a healthy Asian population. Disclosure: J. Yoo: None. W. Lee: None. J. Park: None. J. Lee: None. Y. Kang: None. C. Jung: None. Y. Cho: None. C. Park: None. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
34. PI-04 - Visceral adiposity index predicts the conversion of metabolically healthy obesity to an unhealthy phenotype.
- Author
-
Lee, Woo Je, Kang, Yu Mi, Jung, Chang Hee, Cho, Yun Kyung, Jang, Jung Eun, Hwang, Jenie Yoonoo, Kim, Eun Hee, Park, Joong-Yeol, and Kim, Hong-Kyu
- Subjects
- *
BARIATRIC surgery , *METABOLIC disorders , *MEDICAL research - Published
- 2016
- Full Text
- View/download PDF
35. PJ-02 - Mortality and causes of death from 2002 to 2013 in a national sample of diabetic patients in Korea.
- Author
-
Kang, Yu Mi, Kim, Ye Ji, Park, Joong-Yeol, Lee, Woo Je, and Jung, Chang Hee
- Subjects
- *
DIABETES , *MORTALITY , *KOREANS , *CAUSES of death , *MEDICAL care , *MEDICAL practice , *DISEASES - Published
- 2016
- Full Text
- View/download PDF
36. ChemInform Abstract: A New Isoflavone Glycoside from the Stems of Tilia taquetii Schneider.
- Author
-
Kang, Yu Mi and Lee, Nam Ho
- Published
- 2011
- Full Text
- View/download PDF
37. C1q/TNF-related protein-9 inhibits cytokine-induced vascular inflammation and leukocyte adhesiveness via AMP-activated protein kinase activation in endothelial cells.
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Lee, Yoo La, Seol, So Mi, Yoon, Hae Kyeong, Kang, Sang-Wook, Lee, Woo Je, and Park, Joong-Yeol
- Subjects
- *
INFLAMMATION , *CARDIOTONIC agents , *TUMOR necrosis factors , *LEUCOCYTES , *PROTEIN kinases , *ENDOTHELIAL cells , *ADIPONECTIN , *CYTOKINES - Abstract
Although recent studies have reported cardioprotective effects of C1q/TNF-related protein 9 (CTRP9), the closet adiponectin paralog, its role on cytokine-induced endothelial inflammation is unknown. We investigated whether CTRP9 prevented inflammatory cytokine-induced nuclear factor-kappa B (NF-κB) activation and inhibited the expression of adhesion molecules and a chemokine in the vascular endothelial cell. We used human aortic endothelial cells (HAECs) to examine the effects of CTRP9 on NF-κB activation and the expression of NF-κB-mediated genes, including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1). Tumor necrosis factor alpha (TNFα) was used as a representative proinflammatory cytokine. In an adhesion assay using THP-1 cells, CTRP9 reduced TNFα-induced adhesion of monocytes to HAECs. Treatment with CTRP9 significantly decreased TNFα-induced activation of NF-κB, as well as the expression of ICAM-1, VCAM-1, and MCP-1. In addition, treatment with CTRP9 significantly increased the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC), the downstream target of AMPK. The inhibitory effect of CTRP9 on the expression of ICAM-1, VCAM-1, and MCP-1 and monocyte adhesion to HAECs was abolished after transfection with an AMPKα1-specific siRNA. Our study is the first to demonstrate that CTRP9 attenuates cytokine-induced vascular inflammation in endothelial cells mediated by AMPK activation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
38. The risk of chronic kidney disease in a metabolically healthy obese population.
- Author
-
Jung, Chang Hee, Lee, Min Jung, Kang, Yu Mi, Hwang, Jenie Y, Kim, Eun Hee, Park, Joong-Yeol, Kim, Hong-Kyu, and Lee, Woo Je
- Subjects
- *
BIOLOGICAL models , *CHI-squared test , *CHRONIC kidney failure , *GLOMERULAR filtration rate , *KIDNEYS , *LONGITUDINAL method , *MULTIVARIATE analysis , *RISK assessment , *TIME , *PHENOTYPES , *BODY mass index , *DISEASE incidence , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator , *DIAGNOSIS - Abstract
Obesity has become an important risk factor for chronic kidney disease (CKD). The metabolically healthy obese (MHO) phenotype refers to obese individuals with a favorable metabolic profile. However, its prognostic value remains controversial and may depend on the health outcome being investigated. To assess this, we examined the risk of MHO phenotype with incident CKD in a Korean population of 41,194 people without CKD. Individuals were stratified by body mass index (cutoff value, 25.0 kg/m(2)) and metabolic health state (assessed using Adult Treatment Panel-III criteria). Incident CKD was defined as a glomerular filtration rate of <60 ml/min per 1.73 m(2) calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Over the median follow-up period of 38.7 months, 356 of the individuals developed incident CKD. Compared with the metabolically healthy nonobese (MHNO) group, the MHO group showed increased risk of incident CKD with a multivariate-adjusted hazard ratio of 1.38 (95% CI, 1.01-1.87). Nonobese but metabolically unhealthy individuals were at an increased risk of incident CKD (multivariate-adjusted hazard ratio, 1.37 (95% CI, 1.02-1.93)) than the MHNO group. Metabolically unhealthy obese individuals were at the highest risk of incident CKD. Thus, a healthy metabolic profile does not protect obese adults from incident CKD. Hence, it is important to consider metabolic health along with obesity when evaluating CKD risk. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
39. Differential expression of immune-associated cancer regulatory genes in low- versus high-dose-rate irradiated AKR/J mice
- Author
-
Shin, Suk Chul, Lee, Kyung-Mi, Kang, Yu Mi, Kim, Kwanghee, Lim, Seon Ah, Yang, Kwang Hee, Kim, Ji Young, Nam, Seon Young, and Kim, Hee Sun
- Subjects
- *
GENE expression , *CANCER genes , *MICE as carriers of disease , *GENETIC regulation , *LYMPHOMAS , *RADIATION-protective agents , *IMMUNE response , *ANTINEOPLASTIC agents ,LEUKEMIA genetics - Abstract
Abstract: AKR/J mice carrying leukemia viral inserts develop thymic lymphoma. Recently, we demonstrated that the incidence of thymic lymphoma was decreased when these mice were raised in a low-dose-rate γ-irradiation facility. In contrast, mice irradiated at a high-dose rate developed severe thymic lymphoma and died much earlier. To understand the genetic changes occurred by low- versus high-dose-rate γ-irradiation whole genome microarray was performed. Both groups of mice demonstrated up-regulation of Ifng, Igbp1, and IL7 in their thymuses, however, mice exposed to high-dose-rate γ-irradiation exhibited marked down-regulation of Sp3, Il15, Traf6, IL2ra, Pik3r1, and Hells. In contrast, low-dose-rate irradiated mice demonstrated up-regulation of Il15 and Jag2. These gene expression profiles imply the impaired immune signaling pathways by high-dose-rate γ-irradiation while the facilitation of anti-tumor immune responses by low-dose-rate γ-irradiation. Therefore, our data delineate common and distinct immune-associated pathways downstream of low- versus high-dose-rate irradiation in the process of cancer progression in AKR/J mice. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
40. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation
- Author
-
Shin, Suk Chul, Lee, Kyung-Mi, Kang, Yu Mi, Kim, Kwanghee, Kim, Cha Soon, Yang, Kwang Hee, Jin, Young-Woo, Kim, Chong Soon, and Kim, Hee Sun
- Subjects
- *
PHYSIOLOGICAL effects of ionizing radiation , *CYTOKINES , *IONIZING radiation dosage , *LABORATORY mice , *LYMPHOCYTES , *HORMESIS , *BODY weight , *IMMUNOREGULATION - Abstract
Abstract: While a high-dose of ionizing radiation is generally harmful and causes damage to living organisms, a low-dose of radiation has been shown to be beneficial in a variety of animal models. To understand the basis for the effect of low-dose radiation in vivo, we examined the cellular and immunological changes evoked in mice exposed to low-dose radiation at very low (0.7mGy/h) and low (3.95mGy/h) dose rate for the total dose of 0.2 and 2Gy, respectively. Mice exposed to low-dose radiation, either at very low- or low-dose rate, demonstrated normal range of body weight and complete blood counts. Likewise, the number and percentage of peripheral lymphocyte populations, CD4+ T, CD8+ T, B, or NK cells, stayed unchanged following irradiation. Nonetheless, the sera from these mice exhibited elevated levels of IL-3, IL-4, leptin, MCP-1, MCP-5, MIP-1α, thrombopoietin, and VEGF along with slight reduction of IL-12p70, IL-13, IL-17, and IFN-γ. This pattern of cytokine release suggests the stimulation of innate immunity facilitating myeloid differentiation and activation while suppressing pro-inflammatory responses and promoting differentiation of naïve T cells into T-helper 2, not T-helper 1, types. Collectively, our data highlight the subtle changes of cytokine milieu by chronic low-dose γ-radiation, which may be associated with the functional benefits observed in various experimental models. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
41. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
- Author
-
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, and Wiviott SD
- Subjects
- Humans, Renal Insufficiency, Chronic mortality, Renal Insufficiency, Chronic drug therapy, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 mortality, Diabetes Mellitus, Type 2 complications, Female, Male, Treatment Outcome, Aged, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Cardiovascular Diseases mortality
- Abstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear., Methods: This was a collaborative trial-level meta-analysis from the SGLT2i Meta-analysis Cardio-Renal Trialists Consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i across 3 patient populations (patients with diabetes at high risk for atherosclerotic cardiovascular disease, heart failure [HF], or chronic kidney disease). The outcomes of interest were MACE (composite of cardiovascular death, myocardial infarction , or stroke), individual components of MACE (inclusive of fatal and nonfatal events), all-cause mortality, and death subtypes. Effect estimates for SGLT2i versus placebo were meta-analyzed across trials and examined across key subgroups (established atherosclerotic cardiovascular disease, previous myocardial infarction, diabetes, previous HF, albuminuria, chronic kidney disease stages, and risk groups)., Results: A total of 78 607 patients across 11 trials were included: 42 568 (54.2%), 20 725 (26.4%), and 15 314 (19.5%) were included from trials of patients with diabetes at high risk for atherosclerotic cardiovascular disease, HF, or chronic kidney disease, respectively. SGLT2i reduced the rate of MACE by 9% (hazard ration [HR], 0.91 [95% CI, 0.87-0.96], P <0.0001) with a consistent effect across all 3 patient populations ( I
2 =0%) and across all key subgroups. This effect was primarily driven by a reduction in cardiovascular death (HR, 0.86 [95% CI, 0.81-0.92], P <0.0001), with no significant effect for myocardial infarction in the overall population (HR, 0.95 [95% CI, 0.87-1.04], P =0.29), and no effect on stroke (HR, 0.99 [95% CI, 0.91-1.07], P =0.77). The benefit for cardiovascular death was driven primarily by reductions in HF death and sudden cardiac death (HR, 0.68 [95% CI, 0.46-1.02] and HR, 0.86 [95% CI, 0.78-0.95], respectively) and was generally consistent across subgroups, with the possible exception of being more apparent in those with albuminuria ( Pinteraction =0.02)., Conclusions: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of atherosclerotic cardiovascular disease, diabetes, kidney function, or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of cardiovascular death, particularly HF death and sudden cardiac death, without a significant effect on myocardial infarction in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease., Competing Interests: Disclosures Drs Patel, Kang, Im, Sabatine, and Wiviott are members of the TIMI Study Group, which has received institutional grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Inc., Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Saghmos Therapeutics, Inc., Softcell Medical Limited, The Medicines Company, Verve Therapeutics, Inc., and Zora Biosciences. Dr Patel reports consulting fees from Janssen. Dr Neuen reports fees for travel support, advisory boards, scientific presentations, and steering committee roles from AstraZeneca, Alexion, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, Cornerstone Medical Education, Janssen, the limbic, Medscape, and Travere Therapeutics with all honoraria paid to The George Institute for Global Health. Dr Anker reports grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work, or lectures from Actimed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of 2 patent applications regarding MR-proANP (DE 102007010834 and DE 102007022367), but he does not benefit personally from the related issued patents. Dr Bhatt discloses the following relationships: advisory boards for: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, and Stasys; boards of directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), and High Enroll (stock); consultant: Broadview Ventures, GlaxoSmithKline, Hims, SFJ, and Youngene; data monitoring committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial [Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial]), funded by St. Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial [Pulmonary Embolism International Thrombolysis Trial]), Cleveland Clinic, Contego Medical (chair, PERFORMANCE 2 [Protection Against Emboli During Carotid Arter Stenting Using the Neuroguard IEP System]), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial [Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation–Atrial Fibrillation], funded by Daiichi Sankyo; for the ABILITY-DM trial (Randomized Comparison of Abluminus DSE+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global), funded by Concept Medical; for ALLAY-HF (Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure), funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the National Institutes of Health–funded MINT Trial [Myocardial Ischemia and Transfusion]); Honoraria: American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; chair, ACC accreditation oversight committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial [Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting] steering committee funded by Boehringer Ingelheim; AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome] executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial [A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease], funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (course director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS [Cardiovascular Outcomes for People Using Anticoagulation Strategies] operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (deputy editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women’s Hospital who assigned to Lexicon; neither I nor Brigham and Women’s Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, and 89Bio; Royalties: Elsevier (editor, Braunwald’s Heart Disease); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; trustee: American College of Cardiology; Unfunded Research: FlowCo. Dr Butler reports consulting fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll. Dr Cherney has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon and Novo-Nordisk, and received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. Dr Claggett has received consulting fees from Amgen, Cardurion, Corvia, and Novartis. Dr Anand reported receiving personal fees from AstraZeneca during the conduct of the study and personal fees from Amgen, ARCA, Boston Scientific Corporation, Boehringer Ingelheim, LivaNova, and Zensun outside the submitted work. D. Herrington reports funding from the UK Medical Research Council, Kidney Research UK, and Health Data Research UK; and grants to the University of Oxford from Boehringer Ingelheim and Eli Lilly for the EMPA-KIDNEY trial. Dr Inzucchi reports serving as an advisor or consultant to Boehringer Ingelheim, AstraZeneca, Bayer, Novo Nordisk, Merck, Pfizer, Lexicon, Abbott, VTV Therapeutics, and Esperion, and delivering lectures sponsored by Boehringer Ingelheim and AstraZeneca. Dr Jardine is supported by a National Health and Medical Research Council investigator grant; is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, and MSD; has received fees for advisory, steering committee and scientific presentations from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Linx, Chinook, CSL, Janssen, Medscape, MSD, Occuryx, Roche, and Vifor, with any consultancy, honoraria, or travel support paid to her institution. Dr Mahaffey’s financial disclosures can be viewed at http://med.stanford.edu/profiles/kenneth-mahaffey. Dr McGuire has received honoraria for trial leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, CSL Behring, and Eidos and NewAmsterdam; and honoraria for consultancy from Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, CSL Behring, Bayer, Altimmune, Intercept, Alynlam, and Pfizer. Dr McMurray has received payments through Glasgow University from work on clinical trials, consulting, and other activities from Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GSK, KBP Biosciences, and Novartis; has received personal consultancy fees from Alnylam Pharma, Bayer, BMS, George Clinical PTY Ltd, Ionis Pharma, Novartis, Regeneron Pharma, and River 2 Renal Corporation; has received personal lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions Ltd., Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharma. Ltd, Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica health, Intas Pharma, J.B. Chemicals & Pharma Ltd, Lupin Pharma, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharma, The Corpus, Translation Research Group, and Translational Medicine Academy; and is a director of Global Clinical Trial Partners Ltd. Dr Nunez has received personal fees from or is on advisory boards for Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Cytokinetics, Novartis, Novo Nordisk, Rovi, and Vifor Pharma. Dr Neal has received grants for CANVAS and CREDENCE, advisory board, honoraria, travel reimbursement, all from Janssen and all paid to his institution. He has received research support from the Australian National Health and Medical Research Council principal research fellowship and from Janssen, and he has served on advisory boards or has had involvement in continuing medical education programs for Janssen, with any consultancy, honoraria, or travel support paid to his institution. He also notes institutional relationships with AbbVie, Actelion, and Janssen. Dr Packer reports consulting to 89bio, Abbvie, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Medtronic, Moderna, Novartis, Reata, Relypsa, and Salamandra. Dr Staplin has consulted for and received speaker fees from Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. Dr Perkovic has received fees for advisory boards, steering committee roles and travel support from AstraZeneca, Bayer, and Janssen, with all honoraria paid to his employer. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent, and Sarepta. Dr Staplin reports institutional grant support from Boehringer Ingelheim, Lilly, and Novo Nordisk. Dr Vaduganathan has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. Dr Wanner reports personal fees from Boehringer Ingelheim, AstraZeneca, Eli Lilly, and Company, MSD, and Bayer. Dr Wheeler reports honoraria and consultancy fees from Amgen, AstraZeneca (ongoing), Astellas, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Mundipharma, Merck Sharp, Napp, and Dohme, Takeda, Vifor Fresenius, and Zydus. Dr Zannad reports personal fees from 89Bio, Abbott, Acceleron, Applied Therapeutics, Bayer, Betagenon, Boehringer, BMS, CVRx, Cambrian, Cardior, Cereno pharmaceutical, Cellprothera, CEVA, Inventiva, KBP, Merck, NovoNordisk, Owkin, Otsuka, Roche Diagnostics, Northsea, USa2, having stock options at G3Pharmaceutical and equities at Cereno, Cardiorenal, Eshmoun Clinical research and being the founder of Cardiovascular Clinical Trialists. Dr Zhao is an employee of Merck & Co, Inc. and holds Merck stock. Dr Heerspink has received grants or contracts from AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Dimerix, Eli Lilly, Gilead, Janssen, Novo Nordisk, Novartis, and Travere Therapeutics; payment or honoraria for speaking from AstraZeneca and Novo Nordisk. Dr Sabatine reports research grant support through Brigham and Women’s Hospital from Abbott; Amgen; Anthos Therapeutics, Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; Ionis; Merck; Novartis; Pfizer; Saghmos Therapeutics; Verve Therapeutics, and consulting for Amgen; Anthos Therapeutics, Inc.; AstraZeneca; Beren Therapeutics; Boehringer Ingelheim; Dr. Reddy’s Laboratories; Merck; Moderna; Novo Nordisk; Precision BioSciences; and Silence Therapeutics. Dr Wiviott reports research grants from Amgen, AstraZeneca, Janssen, Merck, and Pfizer, consulting fees or honoraria from Icon Clinical and Novo Nordisk, Varian and Harvard Medical School. Dr Wiviott’s spouse, Dr Caroline Fox, is an employee of Vertex, and a former employee of Flagship Pioneering and Merck.- Published
- 2024
- Full Text
- View/download PDF
42. Ralstonia solanacearum Type III Effector RipJ Triggers Bacterial Wilt Resistance in Solanum pimpinellifolium .
- Author
-
Pandey A, Moon H, Choi S, Yoon H, Prokchorchik M, Jayaraman J, Sujeevan R, Kang YM, McCann HC, Segonzac C, Kim CM, Park SJ, and Sohn KH
- Subjects
- Bacterial Proteins genetics, Disease Resistance, Plant Diseases, Ralstonia solanacearum, Solanum
- Abstract
Ralstonia solanacearum causes bacterial wilt disease in solanaceous crops. Identification of avirulence type III-secreted effectors recognized by specific disease resistance proteins in host plant species is an important step toward developing durable resistance in crops. In the present study, we show that R. solanacearum effector RipJ functions as an avirulence determinant in Solanum pimpinellifolium LA2093. In all, 10 candidate avirulence effectors were shortlisted based on the effector repertoire comparison between avirulent Pe_9 and virulent Pe_1 strains. Infection assays with transgenic strain Pe_1 individually carrying a candidate avirulence effector from Pe_9 revealed that only RipJ elicits strong bacterial wilt resistance in S. pimpinellifolium LA2093. Furthermore, we identified that several RipJ natural variants do not induce bacterial wilt resistance in S. pimpinellifolium LA2093. RipJ belongs to the YopJ family of acetyltransferases. Our sequence analysis indicated the presence of partially conserved putative catalytic residues. Interestingly, the conserved amino acid residues in the acetyltransferase catalytic triad are not required for effector-triggered immunity. In addition, we show that RipJ does not autoacetylate its lysine residues. Our study reports the identification of the first R. solanacearum avirulence protein that triggers bacterial wilt resistance in tomato. We expect that our discovery of RipJ as an avirulence protein will accelerate the development of bacterial wilt-resistant tomato varieties in the future.[Formula: see text] Copyright © 2021 The Author(s). This is an open access article distributed under the CC BY 4.0 International license.
- Published
- 2021
- Full Text
- View/download PDF
43. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
- Author
-
Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, and Park JY
- Subjects
- Aged, Blood Glucose analysis, Body Weight drug effects, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Drug Therapy, Combination, Female, Glycated Hemoglobin analysis, Humans, Hypoglycemia chemically induced, Hypoglycemic Agents adverse effects, Male, Metformin adverse effects, Middle Aged, Sulfonylurea Compounds adverse effects, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Hypoglycemic Agents therapeutic use, Insulin Glargine adverse effects, Insulin Glargine therapeutic use, Metformin therapeutic use, Sulfonylurea Compounds therapeutic use
- Abstract
Background: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM)., Methods: This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia., Results: The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects ( n =33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. -0.9±6.0 kg, P =0.011)., Conclusion: The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs., Competing Interests: Sponsorship for this study and article processing charges was funded by Sanofi-Aventis Korea. Dol Mi Kim is an employee at Sanofi-Aventis Korea. No potential conflict of interest relevant to this article was reported except for her., (Copyright © 2019 Korean Diabetes Association.)
- Published
- 2019
- Full Text
- View/download PDF
44. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
- Author
-
Kang YM, Cho YK, Lee J, Lee SE, Lee WJ, Park JY, Kim YJ, Jung CH, and Nauck MA
- Subjects
- Aged, Black People, Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 drug therapy, Exenatide adverse effects, Exenatide therapeutic use, Female, Glucagon-Like Peptides adverse effects, Glucagon-Like Peptides therapeutic use, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents therapeutic use, Liraglutide adverse effects, Liraglutide therapeutic use, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Risk Factors, Treatment Outcome, White People, Asian People, Cardiovascular Diseases chemically induced, Cardiovascular Diseases ethnology, Exenatide pharmacology, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptides pharmacology, Hypoglycemic Agents pharmacology, Liraglutide pharmacology
- Abstract
Background: Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the greatest cardiovascular (CV) benefit., Methods: Three CVOTs reporting effects of long-acting GLP-1 RAs were included: LEADER (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide once weekly). In all studies, the primary endpoint was three-point MACE, comprising CV death, non-fatal myocardial infarction, and non-fatal stroke. Overall effect estimates were calculated as hazard ratios and 95% confidence intervals (CIs) using the random-effects model; subgroup analyses reported in the original studies were similarly analyzed., Results: Overall, statistically significant risk reductions in MACE and CV death were observed. Subgroup analysis indicated a significant racial difference with respect to CV benefit ( P for interaction <0.001), and more substantial risk reductions were observed in subjects of African origin (relative risk [RR], 0.78; 95% CI, 0.60 to 0.99) and in Asians (RR, 0.35; 95% CI, 0.09 to 1.32). However, post hoc analysis (Bonferroni method) revealed that only Asians exhibited a significantly greater CV benefit from treatment, compared with white subjects ( P <0.0001)., Conclusion: Long-acting GLP-1 RAs reduced risks of MACE and CV deaths in high-risk patients with type 2 diabetes mellitus. Our findings of a particularly effective reduction in CV events with GLP-1 RA in Asian populations merits further exploration and dedicated trials in specific populations., Competing Interests: Michael A. Nauck has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from AstraZeneca, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and NovoNordisk. He has also served on the speakers' bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly % Co., Menarini/Berlin Chemie, Merck, Sharp % Dohme, and NovoNordisk., (Copyright © 2019 Korean Diabetes Association.)
- Published
- 2019
- Full Text
- View/download PDF
45. Transplantation of human mobilized mononuclear cells improved diabetic neuropathy.
- Author
-
Min SH, Kim JH, Kang YM, Lee SH, Oh BM, Han KS, Zhang M, Kim HS, Moon WK, Lee H, Park KS, and Jung HS
- Subjects
- Action Potentials, Adult, Animals, Blood Glucose, Cell Line, Coculture Techniques, Humans, Magnetic Resonance Imaging, Male, Mice, Myelin P0 Protein metabolism, Rats, Nude, Rats, Sprague-Dawley, Sciatic Nerve metabolism, Diabetic Nephropathies therapy, Leukocytes, Mononuclear transplantation
- Abstract
Rodent stem cells demonstrated regenerative effects in diabetic neuropathy via improvement in nerve perfusion. As a pre-clinical step, we explored if human mobilized mononuclear cells (hMNC) would have the same effects in rats. hMNC were injected into Rt. hind-limb muscles of streptozotocin-induced diabetic nude rats, and the grafts were monitored using with MRI. After 4 weeks, the effects were compared with those in the vehicle-injected Lt. hind limbs. Nerve conduction, muscle perfusion and gene expression of sciatic nerves were assessed. Induction of diabetes decreased nerve function and expression of Mpz and Met in the sciatic nerves, which are related with myelination. hMNC injection significantly improved the amplitude of compound muscle action potentials along with muscle perfusion and sciatic nerve Mpz expression. On MRI, hypointense signals were observed for 4 weeks at the graft site, but their correlation with the presence of hMNC was detectable for only 1 week. To evaluate paracrine effects of hMNC, IMS32 cells were tested with hepatocyte growth factor (HGF), which had been reported as a myelination-related factor from stem cells. We could observe that HGF enhanced Mpz expression in the IMS32 cells. Because hMNC secreted HGF, IMS32 cells were co-cultured with hMNC, and the expression of Mpz increased along with morphologic maturation. The hMNC-induced Mpz expression was abrogated by treatment of anti-HGF. These results suggest that hMNC could improve diabetic neuropathy, possibly through enhancement of myelination as well as perfusion. According to in vitro studies, HGF was involved in the hMNC-induced myelination activity, at least in part.
- Published
- 2018
- Full Text
- View/download PDF
46. Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.
- Author
-
Kang YM and Jung CH
- Abstract
The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies., Competing Interests: No potential conflict of interest relevant to this article was reported., (Copyright © 2017 Korean Endocrine Society.)
- Published
- 2017
- Full Text
- View/download PDF
47. Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance.
- Author
-
Kang YM, Kim F, and Lee WJ
- Abstract
Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues., Competing Interests: No potential conflict of interest relevant to this article was reported., (Copyright © 2017 Korean Diabetes Association.)
- Published
- 2017
- Full Text
- View/download PDF
48. Senp2 expression was induced by chronic glucose stimulation in INS1 cells, and it was required for the associated induction of Ccnd1 and Mafa.
- Author
-
Jung HS, Kang YM, Park HS, Ahn BY, Lee H, Kim MJ, Jang JY, and Kim SW
- Subjects
- Adult, Aged, Animals, Cell Line, Cyclin D1 genetics, Cysteine Endopeptidases genetics, Female, Humans, Insulin-Secreting Cells drug effects, Islets of Langerhans drug effects, Maf Transcription Factors, Large genetics, Male, Mice, Middle Aged, Cyclin D1 metabolism, Cysteine Endopeptidases metabolism, Glucose pharmacology, Insulin-Secreting Cells metabolism, Islets of Langerhans metabolism, Maf Transcription Factors, Large metabolism
- Abstract
Post-translational modification by bonding of small ubiquitin-like modifier (SUMO) peptides influences various cellular functions, and is regulated by SUMO-specific proteases (SENPs). Several proteins have been suggested to have diverse impact on insulin synthesis and secretion through SUMO modification in β cells. However, the role of SUMO modification in β cell mass has not been established. Here, we examined the changes in expression of Senp in INS1 cells and pancreatic islets under diabetes-relevant stress conditions and associated changes in β cell mass. Treatment with 25 mM glucose for 72 h induced Senp2 mRNA expression but not that of Senp1 in INS1 cells. Immunohistochemical staining with anti-SENP2 antibody on human pancreas sections revealed that SENP2 was localized in the nucleus. Moreover, in a patient with type 2 diabetes, SENP2 levels were enhanced, especially in the cytoplasm. Senp2 cytoplasmic levels were also increased in islet cells in obese diabetic mice. Cell number peaked earlier in INS1 cells cultured in high-glucose conditions compared to those cultured in control media. This finding was associated with increased Ccnd1 mRNA expression in high-glucose conditions, and siRNA-mediated Senp2 suppression abrogated it. Mafa expression, unlike Pdx1, was also dependent on Senp2 expression during high-glucose conditions. In conclusion, Senp2 may play a role in β cell mass in response to chronic high-glucose through Cyclin D1 and Mafa.
- Published
- 2016
- Full Text
- View/download PDF
49. Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013.
- Author
-
Kang YM, Kim YJ, Park JY, Lee WJ, and Jung CH
- Subjects
- Adult, Age Distribution, Age Factors, Aged, Aged, 80 and over, Cause of Death, Cerebrovascular Disorders diagnosis, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 drug therapy, Female, Health Surveys, Humans, Hypoglycemic Agents therapeutic use, Male, Middle Aged, Myocardial Ischemia diagnosis, Neoplasms diagnosis, Prognosis, Proportional Hazards Models, Registries, Republic of Korea epidemiology, Risk Assessment, Risk Factors, Sex Distribution, Sex Factors, Time Factors, Cerebrovascular Disorders mortality, Diabetes Mellitus, Type 2 mortality, Myocardial Ischemia mortality, Neoplasms mortality
- Abstract
Background: We aimed to investigate the mortality rate (MR), causes of death and standardized mortality ratio (SMR) in Korean type 2 diabetic patients from 2002 to 2013 using data from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC)., Methods: From this NHIS-NSC, we identified 29,807 type 2 diabetic subjects from 2002 to 2004. Type 2 diabetes was defined as a current medication history of anti-diabetic drugs and the presence of International Classification of Diseases (ICD)-10 codes (E11-E14) as diagnosis. Specific causes of death were recorded according to ICD-10 codes as the following: diabetes, malignant neoplasm, disease of the circulatory system, and other causes., Results: A total of 7103 (23.8 %) deaths were recorded. The MR tended to increase with age. In particular, the ratio of MR for men versus women was the highest in their 40s-50s. The overall SMR was 2.32 and the SMRs attenuated with increasing age. The causes of death ascribed to diabetes, malignant neoplasm, ischemic heart disease, cerebrovascular disease, and other causes were 22.0, 24.8, 6.2, 11.2 and 31.3 %, respectively. The SMRs according to each cause of death were 9.73, 1.76, 2.60, 2.04 and 1.89, respectively., Conclusions: The MRs among type 2 diabetic subjects increased with age, and diabetic men exhibited a higher mortality risk than diabetic women in Korea. Subjects with type 2 diabetes exhibited an excess mortality when compared with the general population. Approximately 78.0 % of the diabetes-related deaths was not ascribed to diabetes, and malignant neoplasm was the most common cause of death among those not recorded as diabetes.
- Published
- 2016
- Full Text
- View/download PDF
50. Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.
- Author
-
Kang YM and Jung CH
- Abstract
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite. Moreover, GLP-1 RAs also exert beneficial roles on multiple organ systems in which the GLP-1 receptors exist, including the cardiovascular system. Cardiovascular effects of GLP-1 RAs have been of great interest since the burden from cardiovascular diseases (CVD) has been unbearably increasing in a diabetic population worldwide, despite strict glycemic control and advanced therapeutic techniques to treat CVD. Preclinical studies have already demonstrated the beneficial effects of GLP-1 on myocardium and vascular endothelium, and many clinical studies evaluating changes in surrogate markers of CVD have suggested potential benefits from the use of GLP-1 RAs. Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment. However, to date, there is only one randomized clinical trial of GLP-1 RAs (the ELIXA study) evaluating major cardiovascular events as their primary outcomes, and in this study, a neutral cardiovascular effect of lixisenatide was observed in high-risk diabetic subjects. Therefore, the results of ongoing CVD outcome trials with the use of GLP-1 RAs should be awaited to elucidate the translation of benefits previously seen in CVD risk marker studies into large clinical trials with primary cardiovascular outcomes.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.